ArticleInfection and drug resistance2025
Clinical Characteristics, Risk Factors and Prognosis of Carbapenem-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Risk Factors and Outcomes of Carbapenem-Resistant PInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To ascertain clinical characteristics, risk factors and prognosis of bloodstream infection (BSI) caused by carbapenem-resistant Methods: A retrospective study (January 2015 to December 2023) was performed on the health records of cancer patients with Results: A total of 361 cancer patients with PA BSI were included, 25.5% (92/361) of which were infected with CRPA. Among the 184 enrolled patients (48 with ST, 136 with HM), the independent risk factors for developing CRPA BSI were platelet counts and recent carbapenem use within 90 days in patients with ST. Presence of multidrug-resistant Conclusion: The mortality rates of CRPA BSI are notably high in both patients with ST and HM. The risk factors for CRPA BSI and mortality may guide and optimize the management of CRPA BSI in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.